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ABSTRACT
Introduction: Clinical guidelines recommend rapid evaluation of patients with suspected lung cancer. There are few 
data concerning delays in the diagnostic process of lung cancer in Portugal and adherence to recommendations. 
The aim of this work is to review and analyze the different phases in the process of diagnosis, staging, therapeutic 
decision and treatment within a pulmonology department.
Methods: Retrospective, single -center cohort study, with identification and analysis of the different stages of the 
pathway taken by patients with suspected lung cancer. The study contemplates the flow design and characterization 
related to waiting times. Descriptive statistical analysis of waiting times in each step and total waiting times and 
comparison with available guidelines.
Results: 77 patients included, predominantly male (72.7%), mean age of 66. Mean time from admission to start of 
treatment was 68 days (±55.2). Most patients underwent bronchoscopy (71.4%), which was conclusive in 54.6%; 
39 patients (50.6%) needed a second exam and 14 (18.2%) a third one. Mean time from multidisciplinary decision 
to treatment was 14 days (±25.6). There were great differences between modalities: 6 days (±8) to chemotherapy, 
5 days (±2) to radiation therapy and 63 days (±33) to surgery. Adherence to guidelines varied between 36.4% and 
50.6% concerning total time and between 44.2% and 58.4% for time from diagnosis to treatment.
Conclusion: Total time of the process exceeded main guidelines in 6 to 26 days; however, there was considerable 
heterogeneity and results do not differ greatly from other published data. Proposing an optimized workflow may 
shorten critical stages and improve global performance, allowing for improvements in doctor and patient’s expecta-
tions.
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INTRODUCTION AND OBJECTIVES
Lung cancer is the main cause of death by 
cancer throughout the world. In 2018, 2,09 million 
new cases were diagnosed, there were 1,76 
million deaths due to lung cancer, and these 
numbers continue to rise steadily1. In Portugal, 
incidence among men is 41.9/100 000 inhabi-
tants and 11.04/100 000 among women, putting 
it in fourth place. Each year incidence has been 
rising around 0.5%2. Mortality remains high: in 
2015 there were 4015 deaths by lung cancer in 
Portugal, 3035 of which in men; amongst women, 
mortality rates have raised from 9.2 to 10.7% 
between 2011 and 2015 and this growing trend 
is consistent3.
Early diagnosis and precise staging of the 
disease is crucial for better outcomes, and this is 
well established through large randomized trials 
and international guidelines2,4–6. Less than 30% 
of patients have early stage cancer eligible for 
surgery or other radical therapy. Delays in diag-
nosis and time until start of treatment have been 
reported as responsible for increases in tumor 
size and stage5, but these findings are not com-
pletely consistent.
Some authors defend the clinical importance 
of obtaining a quick tissue diagnosis has been 
demonstrated, as patients with more than four 
months delay from imaging to diagnosis have sig-
nificantly worse survival6 and may miss the oppor-
tunity to undergo curative intent procedure7.
Also, some studies showed that longer time to 
treatment was a significant negative prognostic 
factor in patients with stage III disease, but others 
have demonstrated that shorter delays are asso-
ciated with shorter survival5. Recently, a review 
of 693 554 patients diagnosed with non -small cell 
lung cancer in the United States showed that 
shorter wait times were associated with a decrea-
sed risk of death in early -stage patients, but poo-
rer survival in patients with advanced disease8.
Available data from studies in the United Sta-
tes shows that time from suspicion of cancer to 
beginning of treatment ranges from 45 to 90 days, 
largely surpassing recommendations9. One of 
these studies, with a large sample of 2 372 pa-
tients, showed considerable differences between 
stages – 90 days for patients with stages I and II, 
and 52 days in those with more advanced disea-
se10. A study in Canada found median time from 
presentation to specialist referral was 27 days 
and a further 23 days to complete investigations. 
The overall time from development of first symp-
toms to starting treatment was 138 days11. The 
Canadian Strategy for Cancer Control recom-
mends that the maximum time to diagnose most 
cancers should not exceed four weeks11, as do 
other guidelines13 -15. However, recommendations 
about waiting times are largely empirically based, 
and there is a lack of strong evidence about dif-
ferences in outcomes.
There remains questioning whether delays in 
diagnosis depend on organizational factors or on 
patients’ variability. Missed opportunities can ha-
ppen at three different stages of the process: at 
the initial assessment, at diagnostic test perfor-
mance and interpretation (imaging, biopsies, sta-
ging work -up), and follow -up and coordination12. 
It is therefore crucial to identify these different 
opportunities at different steps and find out what 
are the key factors that delay the process.
Several strategies have been proposed to im-
prove timely diagnosis. In the United Kingdom, 
the National Health Service proposes new stan-
dards for a timely diagnosis of lung cancer, with 
fast -track diagnostic and assessment pathways 
that allow for a communication of a diagnosis 
within 28 days or 14 days13–15. Other countries 
have published guidelines concerning recommen-
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ded timeframes2,15–20. A recent scoping review 
found that most published studies show non-
-compliance with existing guidelines, although 
with considerable regional differences; treatment 
interval median was 27 days, with only 6 studies 
(in a total of 52) showing adherence to guideline 
timeframes21.
Within this context, the present study tries to 
shed some light in the current situation in a Por-
tuguese scenario. To our knowledge, there is very 
few data concerning delays in the diagnostic pro-
cess of lung cancer in Portugal and adherence to 
recommendations. Despite the existence of a 
universal access health service that can provide 
state -of -the -art therapy to cancer patients in our 
country, that are still considerable organizational 
problems that can impact access, timely diagnosis 
and timely start of therapy. The national health 
authorities recommend maximum response times 
for some diseases, such as cancer20. For lung 
cancer, referral to a specialist should happen 
between 7 and 15 days; multidisciplinary team 
(MDT) meeting should happen 8 days after diag-
nosis, and treatment should start in 15 days; some 
treatments waiting times are defined by law, such 
as radiotherapy (15 days) and oncological surgery 
(15 to 45 days)22.
The present work is part a project designed to 
assess and optimize the process of diagnosis, 
staging and therapeutic decision in patients with 
suspected lung cancer (DiaSTOP).
METHODS
The present study is a retrospective, single-
-center cohort study focused on the analysis the 
different stages of the pathway taken by patients 
with lung cancer through the flow design and 
characterization of the waiting times on each sta-
ge. The pathway starts when a patient is referred 
to specialist consultation to be investigated and 
includes pathological diagnosis (through biopsy 
or cytology), adequate staging (using 8th edition 
TNM classification criteria), MDT assessment and 
treatment decision and finishes when the patient 
begins treatment. All the key phases of the pro-
cess were assessed, in order to build a diagnostic 
work -up pathway reflecting the reality seen in 
clinical practice within the department.
We included patients followed -up at the Pul-
monology department of a tertiary care hospital 
in suburban Lisbon, serving a population of arou-
nd 700 000 people. Inclusion criteria were: adult 
patients admitted or referred to the Department 
in the period comprised between January 2016 
and December 2017, in whom a diagnosis of 
malignant lung neoplasm was made. Patients 
that were found to have other diagnosis or that 
had significant missing data concerning times 
were excluded. Data was extracted from the hos-
pital information system Soarian® and collected 
in a database covering the key stages of the 
process. Phases were organized in three time 
regions and time between each phase was re-
gistered (Figure 1). Region A starts with patient 
admission and includes the main imaging inves-
tigations necessary prior to invasive biopsy stu-
dies. Region B includes the investigations neces-
sary to obtain and confirm histological diagnosis; 
for practical purposes, a pathological exam (in-
cluding biopsy or cytology) will be called “biopsy”. 
Each biopsy procedure performed (bronchosco-
py, thoracentesis, etc.) can be either conclusive 
or inconclusive, leading to a second exam. Re-
gion C starts when a pathological diagnosis is 
confirmed includes MDT discussion and ends 
when any kind of cancer treatment is started.
We performed descriptive statistical analysis 
of each individual waiting time, of total waiting 
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times within each region and of global waiting 
times, using measures of central tendency (mean 
and median), measures of dispersion (standard 
deviation) and measures of position (quartiles 
and extremes). RStudio® version 3.5.1 was used 
for data analysis and graphing. Through software 
packages it was possible to include and exclude 
outliers in the analysis under study in order to 
focus results on reality. Time results were then 
compared with selected available national and 




From a pool of 161 medical records, we ex-
tracted a sample of 77 patients with considerable 
data and admitted according to the defined crite-
ria, with male predominance (56; 72.7%) and a 
mean age of 66 ± 12 years. Patients were referred 
either from outside the hospital (33.8%), mainly 
from primary care, or from inside the hospital 
(66.2%) – mainly from the pulmonology outpatient 
(32.5%), the emergency department (14.3%) and 
other outpatient clinics (11.6%). In some patients 
a lung cancer suspicion arose while they were 
already admitted to a ward (7.8%).
From admission to consultation
Assessment of the diagnostic process allo-
wed us to build a schematic diagram reflecting 
the work -up pathway taken by the majority of 
patients within the department (Figure 1). Con-
cerning Region A, most patients (57) had a prior 
thoracic CT scan; for the remainder 20, a CT 
scan was ordered. In 37 patients (49.4%) a PET 
scan was also scheduled according to interna-
tional guidelines, for diagnostic and/or staging 
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Figure 1. schematic diagram of the pathway taken by patients with suspected lung cancer admitted or referred to the pulmonology 
department.
ti represents time at phase i (A, B, C, …H); CT: thoracic computed tomography; PET: positron emission tomography; MDT: multidisciplinary team; θ represents the number 
of iterations (number of exams).
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purposes; this exam is performed at another 
institution in Lisbon.
Pathologic diagnosis pathway
Concerning Region B, represented in Table 1, 
bronchoscopy was the first exam performed in 
the majority of patients, but it was conclusive in 
54.6% of cases. In total, 39 patients (50.6%) 
needed a second exam and 14 (18.2%) needed 
a third one. Transthoracic needle aspiration was 
more frequently performed as second or third 
exam. In our institution this technique is performed 
by a dedicated interventional radiologist. EBUS 
was not available in our center until mid -2016, so 
not all patients benefited from this technique.
Staging and treatment
Region C corresponds to therapeutic decision 
in a MDT, after obtaining a final diagnosis. Histo-
logical classification of lung cancer is described 
in Table 2, as well as staging according to TNM 
classification (8th edition). Patients initially staged 
using the previous TNM classifications were re-
classified according to the more recent one. Four 
cases lacked a final clinical staging: two were 
transferred to other hospitals before finishing 
work -up, one had a poor performance status to 
further investigation, and one died before finishing 
work -up.
The MDT met weekly and therapeutic modali-
ties were discussed and proposed to the patients. 
Chemotherapy was the treatment modality in 37 
patients (48,1%); 12 (15,6%) were sent for sur-
gery, 8 (10,4%) started chemoradiation, 4 (5,2%) 
radiation alone and 10 (13%) were offered best 
supportive care. Surgery and radiation therapy 
are not available at our hospital, so these patients 
were referred to pre -determined centers if this 
was the case.
Waiting times
Table 3 represents the results of waiting times, 
according to the diagram in figure 1. Mean total 
time from admission to start of therapy was 69 
days (±55.2), with a median of 59 days (8 – 370 
days). Mean time to first biopsy was 12 days 
Delays in lung cancer diagnosis  
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Table 1. Exams performed to obtain pathologic diagnosis.
1st Exam 2nd Exam 3rd Exam
n(%) Conclusive(%) n(%) Conclusive(%) n(%) Conclusive(%)
Bronchoscopy Br 55 (71.4) 54.6 13 (33.3) 85.6 3 (21.4) 33.3
Br + EBUS 2 (2.6) 0 0 – - 0 – -
EBUS 5 (6.5) 60.0 8 (20.5) 50.0 3 (21.4) 0.0
Interventional 
Radiology
TTNA 10 (13.0) 70.0 13 (33.3) 92.3 5 (35.7) 80.0
Pleural Exams Thora 1 (1.3) 100.0 0 – - 0 – -
PB 2 (2.6) 0 3 (7.7) 0 2 (14.3) – -
Surgery Mediastinoscopy 0 – - 1 (2.6) – - 1 (7.1) – -
Surgery 2 (2.6) 100 0 – - 0 – -
Other exams STB 0 – - 1 (2.6) 0 0 – -
n 77 39 14
Br – Bronchoscopy, EBUS – Endobronchial ultrasound; TTNA – Transthoracic needle aspiration; Thora – Thoracentesis; PB – Pleural Biopsy; STB – soft tissue biopsy
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Table 2. Histological classification and staging (according to TNM system 8th ed.); Undefined represents patients with incomplete 







Histology Adenocarcinoma 23 (41.8) 13 (61.9) 36 (46.8)
Squamous cell carcinoma 19 (34.5) 4 (19.1) 23 (29.9)
Small cell carcinoma 9 (16.0) 2 (9.5) 11 (14.3)
Large cell carcinoma 1 (1.8) 2 (9.5) 3 (3.9)
Poorly differentiated / undifferentiated carcinoma 3 (5.5) 0 3 (3.9)
Undefined 1 (1.8) 0 1 (1.3)
Stage IA 2 (3.6) 3 (14.3) 5 (6.5)
IB 2 (3.6) 5 (23.8) 7 (9.1)
IIA 1 (1.8) 0 1 (1.3)
IIB 1 (1.8) 1 (4.8) 2 (2.6)
IIIA 8 (14.3) 1 (4.8) 9 (11.7)
IIIB 10 (17.9) 2 (9.5) 12 (15.6)
IV 30 (53.6) 7 (33.3) 37 (48.1)
X 2 (3.6) 2 (9.5) 4 (5.2)
Table 3. Statistical analysis of waiting times; t represents waiting time (in days) spent in each phase, according to Figure 1.
Number of
observations
















Zone A tA 77 1.9 0 5.9 0 0 0 0 26.0
tB 77 0.2 0 1.4 0 0 0 0 12.0
tC 77 2.1 0 6.0 0 0 0 0 26.0
tD 70 12.7 4.0 24.2 0 1.0 4.0 9.0 124.0
tE 56 12.0 4.0 23.7 0 1.0 4.0 9.0 124.0
Zone B tF1 75 8.3 7.0 5.0 0 5.0 7.0 12.0 22.0
tF2 40 11.5 10.0 7.4 0 6.0 10.0 14.3 42.0
tF3 14 12.3 11.0 6.7 4.0 7.5 11.0 14.0 31.0
Exams tPET 36 40.8 20.5 33.4 2.0 19.8 29.5 50.8 138.0
tTC 20 16.0 14.0 13.5 2.0 5.5 14.0 20.0 53.0
Zone C tG 63 11.2 0 18.3 0 0 0 17.0 74.0
tH 50 7.0 0 21.5 0 0 0 2.1 131.0
tTotal 77 68.6 58.5 55.2 8.0 37.3 58.5 84.0 370.0
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(±23.7). Mean time spent in the pathologic loop 
(from ordering of the first exam to the results of 
the last diagnostic biopsy) was 41,3 days (3 -327). 
There is considerable deviation caused by outliers 
(mostly due to non -clinical reasons, like patient 
refusal to proceed the investigation); mean time 
was 27 days (3 -124) excluding outliers and me-
dian was 27 days for both cases.
Mean time from MDT decision to start of first-
-line therapy (tH) was 7 days (±21.5 days), but with 
considerable differences according to the chosen 
modality: mean time to chemotherapy was 6 days 
(±8 days), mean time to radiation therapy was 5 
days (±2 days), mean time to surgery was 63 days 
(±33).
We compared these results with existing 
guidelines; adherence represents the percentage 
of patients that are concordant with recommended 
times in the UK (NHS and NOLCP), Sweden, 
Australia, Canada and Portuguese recommenda-
tions and legislation (Table 4).
DISCUSSION
Our results show that global waiting times in 
the process of diagnosis and staging in this sam-
ple are significantly longer than most recommen-
ded times in international clinical guidelines and 
national recommendations, and only 36.4% to 
51.9% patients are adherent when considering 
total time. However, there is considerable hete-
rogeneity in specific times of the process. Consi-
dering the first stage of the process, time from 
admission or referral to specialist consultation, 
most patients adhere to guidelines (> 88%). The 
same is true with time to first biopsy, which is 
within accepted times. Considering the second 
phase, region B, representing the “pathological 
loop”, it is important to note that about half of the 
patients needed to undergo a second biopsy, 
adding an average 11.5 days to this phase, and 
a smaller proportion needing a third biopsy. This 
is an acceptable situation in a complex diagnostic 
Delays in lung cancer diagnosis  
and treatment: real-life assessment...
Table 4. Adherence of sample patients to selected guidelines15–19,22. Time (days) represents proposed maximum waiting time for 
each phase; number of patients and percentage in adherence to each guideline.
Institution / Country Time(days) Admission  First Consultation  Diagnosis  Treatment (start)





NOLCP -National Optimal 
Lung Cancer Pathway (UK)15
49 34(44.2%)
28 44 (57.1%)





Optimal Care Pathway for 




Ontario (Canada)19 42 28 (36.4%)
Portugal22 7 -15 68 -72 (88.3% -93.5%)
23 40 (51.9%)
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process like lung cancer, as clinical presentation 
is variable and numerous patient, operator and 
system factor can affect the results of each diag-
nostic exam. However, it is crucial that the first -line 
test should be chosen considering best cost-
-effectiveness and that is not always the case. In 
our center, bronchoscopy is more readily available 
than transthoracic needle aspiration, and this can 
affect diagnostic conclusiveness and add delay if 
a second test is needed. Local availability of 
exams affects both effectiveness and delay; in 
our center, EBUS was not available in 2016 and 
that could affect diagnosis and staging in some 
patients, costing more time. Also, PET scan is 
dependent of other institutions, and we found a 
mean delay of 41 days, when Portuguese guide-
lines recommend 30 days20..
In the third phase of the process, region C, we 
found that it takes an average 13 days from diag-
nosis to MDT discussion; this is a delay that could 
easily be shortened and is probably more related 
to system inefficacies, not patient characteristics. 
Although mean time to treatment (14 days) was 
within most guidelines, there are significant diffe-
rences according to the modality, and surgery 
waiting times are very high, even considering 
broader Portuguese norms that state the oncolo-
gical surgery should take place between 15 and 
45 days22.
Approximately 50% of the patients underwent 
chemotherapy as first line treatment, which is in 
line with the diagnosis of locally advanced or 
metastatic disease. Additionally, when the data 
was collected back in 2016, immunotherapy as 
first line treatment was still pending approval.
To our knowledge, this is the first study speci-
fically addressing waiting times in a lung cancer 
center in Portugal, and this data is important to 
identify key steps and players and to propose an 
optimized design.
Improving diagnostic performance in lung can-
cer within our health system is complex and car-
ries important implications, including more timely 
access to therapy and to potentially curative the-
rapy. We cannot forget that all the process carries 
significant patient anxiety and adding delay will 
contribute to more anxiety and uncertainty23.
It is expected that future implementation of ef-
fective nation -wide screening protocols will increase 
the number of patients with early stage disease, 
who will be candidates to curative therapy24. This 
will add pressure to the present system and presu-
mably increase waiting times, if no measures are 
taken. Increased risk of death due to tumor growth 
has been implicated in missed opportunities for 
following -up suspicious lesions detected radiologi-
cally6,25 and underutilization of definitive therapy26,27. 
We also need more data as to wether a a fast -track 
effective system will contribute to better outcomes 
and survival. Some authors found that survival may 
not improve with a fast -track approach due to the 
“sicker quicker” hypothesis: diagnosis and treat-
ment is made sooner in symptomatic patients, who 
have a higher likelihood of advanced disease, as 
opposed to early stage patients, mostly asympto-
matic28. Impact on survival has been extensively 
explored in the literature, with mixed results29–31.
Timely health system performance in lung can-
cer care presents extensive clinical implications, 
and multiple international studies have shown a 
wide range of delays as patients traverse their 
healthcare systems. A prospective study of 52 
patients in Ontario reported a median delay of 
138 days from symptom development to treat-
ment11, while a Swedish study reported a median 
time of 189 days32 and a Finish study reported a 
delay of 112 days26. As a result, a recent compa-
rison of lung cancer guidelines in the four most 
populous Nordic countries (Sweden, Denmark, 
Finland and Norway) led to the establishment of 
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shorter recommended times from initial referral 
to diagnostic conclusion and staging (26 to 30 
days) and from staging to start of treatment (7 to 
15 days)33. A standardized measurement of time 
intervals and outcome measures may allow more 
robust analysis in health service research in the 
future, with potentially better patient outcome.
We acknowledge that our findings may not 
reflect the present complexity of lung cancer diag-
nosis and treatment, due to huge advances in the 
past few years. More precise molecular diagnosis 
and tailoring of therapy to the patients according 
to new knowledge will surely impact waiting times 
in clinical practice.
In conclusion, although only approximately half 
of our patients met the international recommen-
ded timelines, our results are in line with many 
published international studies. These results 
leave place for improvement which should always 
be sought. Additionally, our findings regarding 
factors responsible for delay in lung cancer care 
are similar to those seen in the existing literatu-
re28,31,34. Lack of overt symptoms in patients with 
early stage lung cancer34 and recognition of subtle 
symptoms of lung cancer35 are other frequently 
implicated barriers to timely care, not approached 
in this study. Careful choice of first diagnostic test 
modality and investigations of comparable stan-
dard should be optimal. It is a priority to facilitate 
access and shorten time to curative treatments, 
like thoracic surgery, of crucial importance in ear-
lier stages of lung cancer.
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